跳至主要内容
临床试验/NCT07272837
NCT07272837招募中不适用

GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention

University of Alberta1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
1
主要终点
Changes in skeletal and cardiac muscle mass

研究概览

简要总结

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

This study involves (3) in-person study visits. At each visit, participants will be asked to:

  • Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
  • Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
  • Complete questionnaires related to demographics, health information, physical activity, and nutrition.
  • Have a blood sample collected from a vein in your arm.
  • Have your blood levels assessed through three finger pricks.
  • Complete three days of food records.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults 18-80 years of age
  • Starting semaglutide for type 2 diabetes or weight loss
  • Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

排除标准

  • Current use of semaglutide for more than 2 weeks
  • Major recent heart issues or other severe health conditions
  • Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
  • Dependence on a mobility aid (unable to participate in exercise MRI)

结局指标

主要结局

Changes in skeletal and cardiac muscle mass

时间窗: 12 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and... | 临床试验